Skovronsky Daniel 4

What Happened
Daniel Skovronsky, EVP, Chief Scientific & Product Officer and President, LRL at Eli Lilly, had 12,684 restricted stock units (RSUs) convert into shares on Feb 1, 2026 (reported as derivative exercise, code M). To satisfy the tax withholding obligation (code F), 5,641.249 of those shares were disposed at $1,037.15 per share, yielding $5,850,821. The RSU conversion showed $0 exercise price (typical for RSU settlements).

Key Details

• Transaction date: 2026-02-01; Form 4 filed 2026-02-03 (appears timely).
• RSUs converted: 12,684 shares (code M, $0 exercise price).
• Shares withheld/sold for taxes: 5,641.249 shares at $1,037.15 = $5,850,821 (code F).
• Approximate shares remaining from this settlement: 12,684 − 5,641.249 = ~7,042.75 shares (net of withholding).
• Footnotes: F1 — reporting person disclaims beneficial ownership except to extent of pecuniary interest; F2 — each restricted stock unit converts to one share.
• This was a withholding sale to cover taxes (routine), not an open-market investment sale.

Context
This was a standard RSU settlement with shares withheld/sold to cover tax liabilities (a common, non-speculative event). The filing shows a conversion of RSUs (derivative exercise) followed by share disposition for tax withholding — often described as a cashless or net-share settlement. This type of transaction typically reflects compensation vesting rather than a directional buy/sell decision by the insider.